Boston Scientific Corporation (BSX) 2024 10-K Earnings Analysis
Boston Scientific Corporation2024 Earnings Analysis
79/100
Boston Scientific Corporation's FY2024 numbers are straightforward on the surface but more interesting underneath: $16.7B of revenue, $1.85B of net income, 68.6% gross margin, and $2.65B of free cash flow. FARAPULSE Launch, Axonics + Silk Road, and Watchman LAA Franchise remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. Gross margin was 68.6% and operating margin was 15.5%, so FY2024 does not look like a year bought with weak pricing or loose cost control. The business looks stable today; the real question is how stable it remains under a tougher operating mix.
Filing analysis
Boston Scientific Corporation 2024 10-K Analysis
This page reads Boston Scientific Corporation's 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 79/100, or grade C.
BSX Earnings Quality
The earnings-quality module scores 82/100, with Gross Margin: 68.6%, Operating Margin: 15.5%. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
BSX Economic Moat Analysis
The moat-strength module scores 85/100, with Watchman LAA Franchise: Category-leading, FARAPULSE Electrophysiology: PFA leadership. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
BSX Free Cash Flow vs Net Income
CF/Net Income: 1.85x is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 78/100. For the diagnostic, start with cash flow vs net income.
BSX Key Risks from the Annual Report
The risk module scores 70/100, with PFA Competitive Response: Medtronic + J&J + Abbott, Goodwill Concentration: 43.4% of assets. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is BSX a High Quality Earnings Stock?
Based on this 2024 filing, BSX passes the first screen for high-quality earnings: the overall grade is C, and the earnings-quality score is 82/100. This is a research screen, not investment advice.
Read the report first
Understand Boston Scientific Corporation first, then decide if it belongs on your watchlist
The BSX score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep BSX with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the BSX report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Earnings Quality
Per the FY2024 10-K income statement, gross margin of 68.6% reflects the medical-device cost structure across Cardiology, Peripheral Interventions, Endoscopy, Urology, and Neuromodulation product lines disclosed in the segment footnote.
Per the FY2024 10-K income statement, operating margin of 15.5% reflects acquired-intangible amortization on the M&A portfolio offsetting strong gross-margin economics. MD&A attributes margin trajectory to Watchman LAA-closure growth and emerging electrophysiology contribution.
Per the FY2024 cash flow statement, OCF of $3.4B is 1.85x net income of $1.85B — the spread reflects acquired-intangible amortization on the multi-year M&A footprint plus standard depreciation.
Per the FY2024 Cardiology segment MD&A, the Watchman left atrial appendage closure device franchise has grown across multi-year periods. Procedure-volume growth and competitive dynamics versus emerging entrants (e.g., Abbott Amplatzer Amulet per the FDA-approval disclosure) are tracked in supplemental investor tables.
There is enough internal consistency in FY2024 to trust the numbers: $1.85B of net income, $2.65B of free cash flow, and 68.6% gross margin all fit together. FARAPULSE Launch sits close enough to the core workflow that it supports both margin retention and cash conversion, and Axonics + Silk Road reinforces that pattern. That left the company with 15.5% operating margin before capital allocation choices came into view. Reported profit is converting into cash at a healthy rate, which reduces the odds that the FY2024 result is being flattered by accruals.
Moat Strength
Per the FY2024 Cardiology segment MD&A, the Watchman left atrial appendage closure device — a structural-heart category — has been the principal franchise driver. Watchman FLX Pro is the latest-generation device per the publicly-disclosed product communications.
Per the FY2024 Cardiology segment MD&A and the January 2024 FDA-approval press release, FARAPULSE is the pulsed field ablation (PFA) system for atrial fibrillation. PFA is described in clinical and trade-press coverage as a multi-year category transition from radiofrequency and cryo ablation toward field-based therapy.
Per the FY2024 MedSurg segment disclosures, Boston Scientific's MedSurg portfolio includes Endoscopy (gastrointestinal, pulmonary), Urology (stones, BPH treatment via Rezum, prosthetic urology), and Neuromodulation (spinal cord stimulation including Spectra WaveWriter, deep brain stimulation).
Goodwill of $17.1B on $39B assets equals 43.4% per the FY2024 balance sheet — reflecting the multi-year M&A cadence including BTG (2019, $4.2B per the closing press release), Preventice Solutions (2021), Baylis Medical (2022), Axonics (2024 per the closing press release), and Silk Road Medical (2024).
The filing points first to FARAPULSE Launch and Axonics + Silk Road when you ask why customers do not switch casually. Watchman LAA Franchise and FARAPULSE Electrophysiology show that the advantage is reinforced by adjacent capabilities rather than isolated in one corner of the portfolio. It helps that the FY2024 numbers do not fight the story: 8.5% ROE came with a still-readable cash profile. Per the FY2024 annual report and company disclosures, a rival can still win share, but it has to break an embedded process rather than only undercut a list price.
Capital Allocation
Per the FY2024 cash flow statement, FCF of $2.6B (OCF $3.4B minus capex $0.79B) supports the share-repurchase program and ongoing M&A — including the 2024 Axonics and Silk Road Medical acquisitions per the respective closing press releases.
Per successive 10-K M&A disclosures and closing press releases, Boston Scientific has executed multi-year programmatic bolt-on M&A. 2024 saw Axonics (sacral neuromodulation) and Silk Road Medical (transcarotid artery revascularization) acquisitions close per the respective announcements.
Per the FY2024 capital-return disclosures, Boston Scientific does not pay a regular dividend. Capital is allocated principally to M&A reinvestment and selective share repurchases as described in the framework.
$0.79B capex on $16.7B revenue equals 4.7% — modest for a medical-device manufacturer; capex funds manufacturing-capacity expansion across the diversified-product portfolio.
Once capex was covered, the business still produced $2.65B of free cash flow, which is the real source of optionality in the file. Per the FY2024 annual report and company disclosures, because capex consumes only 4.7% of revenue, most of the capital-allocation debate happens after the platform is already funded. $414M of cash means the balance sheet is a support for execution, not the central source of stress. The company is returning capital through two channels at once: recurring dividends and opportunistic buybacks.
Key Risks
Per the FY2024 Risk Factors and PFA-category trade-press coverage, FARAPULSE faces emerging competition from Medtronic's PulseSelect (FDA-approved 2023 per the regulatory disclosure), J&J's Varipulse (under FDA review per the trial-registry disclosures), and Abbott's Volt PFA System (under regulatory review). Competitive dynamics shape the multi-year category-share trajectory.
Per the FY2024 balance sheet, $17.1B goodwill concentrates impairment risk on the BTG, Preventice, Baylis, Axonics, and Silk Road reporting units. Impairment testing follows the disclosed policy.
Per the FY2024 Risk Factors and CMS public coverage decisions, Watchman procedures depend on Medicare coverage and reimbursement-rate setting. CMS rule-makings affecting LAA-closure procedures track in public communications.
Per the FY2024 Risk Factors, hospital capital equipment orders for capital electrophysiology systems and other capital products track hospital-budget cycles.
The practical risk frame for FY2024 is a group of linked operating pressures rather than one clean headline. The linkage between demand, mix, and cash generation is what makes the risk file worth respecting. Goodwill at 43.4% of assets keeps acquisition discipline inside the risk conversation. The business looks stable today; the real question is how stable it remains under a tougher operating mix.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.